Table 1.
Baseline demographics, characteristics, clinical and pharmacotherapy history
| Variable | Empagliflozin, n = 46 [n (%)] | Placebo, n = 50 [n (%)] | P |
|---|---|---|---|
| Male, n (SD) | 38 (82.6) | 39 (78.0) | 0.62 |
| age, years (SD) | 63.9 (10.4) | 64.6 (11.6) | 0.73 |
| Body weight, kg (SD) | 70.1 (13.7) | 68.1 (14.4) | 0.49 |
| BMI, kg/m2 (SD) | 25.2 (3.7) | 25.2 (4.1) | 0.99 |
| DM duration, months (SD) | 38.3 (43.4) | 32.4 (43.3) | 0.51 |
| Current smoker, n (%) | 24 (52.2) | 27 (54.0) | 0.92 |
| Systolic blood pressure, mmHg (SD) | 129.7 (11.9) | 123.1 (15.7) | 0.11 |
| Heart rate, bpm (SD) | 70.3 (11.0) | 71.5 (11.4) | 0.78 |
| Medical history | |||
| Cerebrocardiovascular disease, n (%) | 7 (15.2) | 11 (22.0) | 0.44 |
| Hypertension, n (%) | 38 (82.6) | 39 (78.0) | 0.62 |
| Dyslipidemia, n (%) | 34 (73.9) | 36 (72.0) | 1.00 |
| Culprit lesion | |||
| Left anterior descending artery, n (%) | 25 (54.3) | 34 (68.0) | 0.35 |
| Blood sampling test | |||
| Max CK, IU/L (SD) | 2080.7 (2461.6) | 2358.7(2829.1) | 0.61 |
| HbA1c, % (SD) | 6.82 (1.00) | 6.89 (0.92) | 0.73 |
| LDL-C, mg/dL (SD) | 87.5 (29.6) | 87.8 (29.1) | 0.96 |
| HDL-C, mg/dL (SD) | 45.4 (12.7) | 46.0 (10.2) | 0.78 |
| Triglycerides, mg/dL (SD) | 161.7 (119.7) | 135.9 (54.4) | 0.18 |
| Uric acid, mg/dL (SD) | 5.8 (1.4) | 5.7 (1.5) | 0.94 |
| Creatinine, mg/dL (SD) | 0.92 (0.2) | 0.92 (1.2) | 0.39 |
| eGFR, mL/min/1.73 m2 (SD) | 64.6 (15.0) | 66.1 (15.7) | 0.62 |
| Hematocrit, % (SD) | 40.5 (4.6) | 40.3 (4.2) | 0.86 |
| NT-pro BNP, pg/mL (SD) | 1028.7 (1105.6) | 1270.6 (1521.0) | 0.45 |
| Medical therapy | |||
| β-blocker, n (%) | 41 (89.1) | 38 (76.0) | 0.11 |
| ARB, n (%) | 22 (47.8) | 19 (38.0) | 0.41 |
| ACEI, n (%) | 23 (50.0) | 28 (56.0) | 0.68 |
| Statin, n (%) | 44 (95.7) | 48 (96.0) | 1.00 |
| Spironolactone, n (%) | 11 (23.9) | 12 (24.0) | 1.00 |
| Diuretics, n (%) | 8 (17.4) | 11 (22.0) | 0.62 |
| Metformin, n (%) | 7 (15.2) | 6 (12.0) | 0.77 |
| DPP-4 inhibitor, n (%) | 20 (43.5) | 23 (46.0) | 0.84 |
| ASA/P2Y12 Inhibitor, n (%) | 46 (100) | 50 (100) | 1.00 |
| DOAC, n (%) | 3 (6.5) | 3 (6.0) | 1.00 |
n (SD), number (standard deviation); A1c, glycated hemoglobin; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; ASA, acetylsalicylic acid; BMI: body mass index; CK, creatine kinase; DM, diabetes mellitus; DOAC, direct oral anticoagulant; DPP-4, Dipeptidyl Peptidase-4; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NT-Pro BNP, N-terminal pro b-type natriuretic peptide